The United Kingdom’s stock market has recently faced challenges, with the FTSE 100 index slipping amid concerns over weak trade data from China, highlighting the interconnectedness of global economies. In such a climate, identifying stocks that are priced below their intrinsic value can present compelling opportunities for investors seeking to capitalize on potential long-term growth despite short-term market fluctuations.
Top 10 Undervalued Stocks Based On Cash Flows In The United Kingdom
|
Name |
Current Price |
Fair Value (Est) |
Discount (Est) |
|
Tristel (AIM:TSTL) |
£3.82 |
£7.59 |
49.7% |
|
SDI Group (AIM:SDI) |
£0.77 |
£1.43 |
46.2% |
|
RHI Magnesita (LSE:RHIM) |
£28.90 |
£55.80 |
48.2% |
|
Playtech (LSE:PTEC) |
£3.518 |
£6.66 |
47.2% |
|
Oxford Biomedica (LSE:OXB) |
£6.26 |
£12.24 |
48.9% |
|
Mitie Group (LSE:MTO) |
£1.78 |
£3.41 |
47.7% |
|
M&G (LSE:MNG) |
£3.153 |
£6.19 |
49% |
|
Fevertree Drinks (AIM:FEVR) |
£7.97 |
£14.94 |
46.7% |
|
Entain (LSE:ENT) |
£5.378 |
£10.07 |
46.6% |
|
B90 Holdings (AIM:B90) |
£0.023 |
£0.045 |
48.8% |
Here we highlight a subset of our preferred stocks from the screener.
Overview: Serica Energy plc, along with its subsidiaries, is involved in the identification, acquisition, exploration, and exploitation of oil and gas reserves in the United Kingdom and has a market capitalization of £1.03 billion.
Operations: The company generates revenue from its oil and gas exploration, development, production, and related activities amounting to $601.43 million.
Estimated Discount To Fair Value: 30.7%
Serica Energy is trading significantly below its estimated future cash flow value and 30.7% under fair value, suggesting it may be undervalued based on cash flows. Despite a recent net loss of $51.82 million, earnings are forecast to grow at 35.99% annually, with revenue growth outpacing the UK market average. The company’s strategic acquisition in the Greater Laggan Area enhances its production capabilities and positions it for organic growth in a key gas processing region.
Overview: AstraZeneca PLC is a biopharmaceutical company engaged in the discovery, development, manufacture, and commercialization of prescription medicines, with a market cap of £216.52 billion.
Operations: The company’s revenue is primarily generated from its Pharmaceuticals segment, which accounted for $60.44 billion.
Estimated Discount To Fair Value: 41.6%
AstraZeneca is trading significantly below its estimated future cash flow value, indicating potential undervaluation. Despite a high debt level, the company has shown robust earnings growth of 33.7% over the past year and is forecasted to grow earnings by 13.5% annually, outpacing the UK market average. Recent U.S. approval of Datroway for TNBC treatment could enhance revenue streams, supporting AstraZeneca’s strategic focus on innovative oncology treatments and strengthening its financial position amidst ongoing global expansion efforts.
